ArticleMolecular cancer2008
Potential role of miR-9 and miR-223 in recurrent ovarian cancer.
Article in Molecular cancer, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 165 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
165 citing papers in PubMed, 2 syntheses or guidelines pooled it, 301 citations in OpenAlex.
- Potential role of microRNA‑223‑3p in the tumorigenesis of hepatocellular carcinoma: A comprehensive study based on data mining and bioinformatics.Molecular medicine reports · 2018Pooled it
- Prognostic value of abnormally expressed lncRNAs in ovarian carcinoma: a systematic review and meta-analysis.Oncotarget · 2017Pooled it
- Circulating microRNAs Expression as Prognosis Biomarker of Cholangiocarcinoma.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- Long Non-Coding RNA LINC01116 Promotes the Proliferation of Lung Adenocarcinoma by Targeting miR-9-5p/CCNE1 Axis.Journal of cellular and molecular medicine · 2024Article
- Unraveling the extracellular vesicle network: insights into ovarian cancer metastasis and chemoresistance.Molecular cancer · 2024Review
- MiR-223-3p in Cancer Development and Cancer Drug Resistance: Same Coin, Different Faces.International journal of molecular sciences · 2024Review
- Non-coding RNAs as therapeutic targets in cancer and its clinical application.Journal of pharmaceutical analysis · 2024Review
- Diagnostic value of plasma-derived exosomal miR-223 for epithelial ovarian cancer.BMC women's health · 2024Article
- A diagnostic miRNA panel to detect recurrence of ovarian cancer through artificial intelligence approaches.Journal of cancer research and clinical oncology · 2023Article
- Deregulated miRNA clusters in ovarian cancer: Imperative implications in personalized medicine.Genes & diseases · 2022Review
- The potential applications of microparticles in the diagnosis, treatment, and prognosis of lung cancer.Journal of translational medicine · 2022Review
- Initiation and elongation factor co-expression correlates with recurrence and survival in epithelial ovarian cancer.Journal of ovarian research · 2022Article
- Review
- The Role of microRNAs in the Mammary Gland Development, Health, and Function of Cattle, Goats, and Sheep.Non-coding RNA · 2021Review
- Role of Circulating miRNAs in Therapeutic Response in Epithelial Ovarian Cancer: A Systematic Revision.Biomedicines · 2021Review
- Distribution of microRNA profiles in pre-clinical and clinical forms of murine and human prion disease.Communications biology · 2021Article
- MicroRNAs as Biomarkers for Early Diagnosis, Prognosis, and Therapeutic Targeting of Ovarian Cancer.Journal of oncology · 2021Review
- Predicting 3D Structure, Cross Talks, and Prognostic Significance ofFrontiers in oncology · 2021Article
- Integrated microRNA and mRNA signatures associated with overall survival in epithelial ovarian cancer.PloS one · 2021Article
- MicroRNA Expression Changes and Integrated Pathways Associated With Poor Outcome in Canine Osteosarcoma.Frontiers in veterinary science · 2021Article
105 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicroRNAs (miRNAs) are small, noncoding RNAs that negatively regulate gene expression by binding to target mRNAs. miRNAs have not been comprehensively studied in recurrent ovarian cancer, yet an incurable disease.
resultsUsing real-time RT-PCR, we obtained distinct miRNA expression profiles between primary and recurrent serous papillary ovarian adenocarcinomas (n = 6) in a subset of samples previously used in a transcriptome approach. Expression levels of top dysregulated miRNA genes, miR-223 and miR-9, were examined using TaqMan PCR in independent cohorts of fresh frozen (n = 18) and FFPE serous ovarian tumours (n = 22). Concordance was observed on TaqMan analysis for miR-223 and miR-9 between the training cohort and the independent test cohorts. Target prediction analysis for the above miRNA "recurrent metastatic signature" identified genes previously validated in our transcriptome study. Common biological pathways well characterised in ovarian cancer were shared by miR-9 and miR-223 lists of predicted target genes. We provide strong evidence that miR-9 acts as a putative tumour suppressor gene in recurrent ovarian cancer. Components of the miRNA processing machinery, such as Dicer and Drosha are not responsible for miRNA deregulation in recurrent ovarian cancer, as deluded by TaqMan and immunohistochemistry.
conclusionWe propose a miRNA model for the molecular pathogenesis of recurrent ovarian cancer. Some of the differentially deregulated miRNAs identified correlate with our previous transcriptome findings. Based on integrated transcriptome and miRNA analysis, miR-9 and miR-223 can be of potential importance as biomarkers in recurrent ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.